Thermo chief sees signs of R&D spend upswing

- Last updated on GMT

Laboratory equipment company Thermo Electron managed to raise its
revenues in the fourth quarter of 2003 in the face of sluggish
investment in R&D by the pharma and biotech industries, but
believes there are signs of an upturn in spending.

Fourth-quarter revenues were $583.4 million, up 3 per cent year-on-year, although net income slipped to $62 million, or $0.37 per share, from $87 million ($0.51).

"No question, the overall tone of business is improving across all our markets,"​ said Marijn Dekkers, Thermo's chief executive.

Thermo's Life and Laboratory Sciences segment fourth-quarter revenues up 13 per cent to $377 million. Organic growth was 5 per cent, primarily a result of strong sales of our mass spectrometry instruments and rapid diagnostic tests used to detect flu.

The company said that several new products generated strong orders in the fourth quarter, including the Finnigan LTQ FT hybrid and Finnigan LTQ linear ion trap mass spectrometers, as well as the Shandon Excelsior automated tissue processor.

Mr Dekkers continued: "With good momentum going into 2004, our goal is to report $0.25-$0.27 in adjusted EPS for the first quarter and $1.23-$1.28 for the full year."

Related news

Related products

show more

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Follow us

Products

View more

Webinars